Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields.
The use of stents for vascular disease has resulted in a paradigm shift with significant improvement in therapeutic outcomes. Polymer-coated drug-eluting stents (DES) have also significantly reduced the incidence of reobstruction post stenting, a disorder termed in-stent restenosis. However, the current DESs lack the capacity for adjustment of the drug dose and release kinetics to the disease status of the treated vessel. We hypothesized that these limitations can be addressed by a strategy combining magnetic targeting via a uniform field-induced magnetization effect and a biocompatible magnetic nanoparticle (MNP) formulation designed for efficient entrapment and delivery of paclitaxel (PTX). Magnetic treatment of cultured arterial smooth muscle cells with PTX-loaded MNPs caused significant cell growth inhibition, which was not observed under nonmagnetic conditions. In agreement with the results of mathematical modeling, significantly higher localization rates of locally delivered MNPs to stented arteries were achieved with uniform-field-controlled targeting compared to nonmagnetic controls in the rat carotid stenting model. The arterial tissue levels of stent-targeted MNPs remained 4- to 10-fold higher in magnetically treated animals vs. control over 5 days post delivery. The enhanced retention of MNPs at target sites due to the uniform field-induced magnetization effect resulted in a significant inhibition of in-stent restenosis with a relatively low dose of MNP-encapsulated PTX (7.5 microg PTX/stent). Thus, this study demonstrates the feasibility of site-specific drug delivery to implanted magnetizable stents by uniform field-controlled targeting of MNPs with efficacy for in-stent restenosis.
Chorny
Michael
M
Division of Cardiology Research, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
Fishbein
Ilia
I
Yellen
Benjamin B
BB
Alferiev
Ivan S
IS
Bakay
Marina
M
Ganta
Srinivas
S
Adamo
Richard
R
Amiji
Mansoor
M
Friedman
Gary
G
Levy
Robert J
RJ
D000818:Animals; D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D016503:Drug Delivery Systems; D006083:Graft Occlusion, Vascular / Q000517:prevention & control; D008280:Magnetics; D008297:Male; D053768:Metal Nanoparticles / Q000008:administration & dosage* / Q000648:ultrastructure; D046529:Microscopy, Electron, Transmission; D017239:Paclitaxel / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D015607:Stents
D017239:Paclitaxel
J Vasc Interv Radiol. 2005 Mar;16(3):331-8
15758128
Cancer Chemother Pharmacol. 2007 Nov;60(6):907-14
17375303
Biochim Biophys Acta. 1993 Jul 11;1157(3):233-40
8323953
Circulation. 2003 Aug 19;108(7):788-94
12900339
J Control Release. 2002 Oct 30;83(3):401-14
12387948
Biochem Biophys Res Commun. 1991 Jun 14;177(2):861-6
2049107
J Pharm Sci. 1997 Dec;86(12):1458-63
9423162
Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):698-703
18182491
Biomed Chromatogr. 2007 Mar;21(3):310-7
17221932
Eur Heart J. 2009 Jan;30(1):16-24
19033260
Ann Pharmacother. 2004 Apr;38(4):661-9
14766994
J Endovasc Ther. 2006 Dec;13(6):701-10
17154704
J Control Release. 2001 May 14;72(1-3):191-202
11389998
N Engl J Med. 2007 Mar 8;356(10):1009-19
17296822
J Endovasc Ther. 2007 Aug;14(4):460-8
17696619
Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):159-64
16371477
Neth Heart J. 2007;15(11):395-6
18612390
Biomaterials. 1992;13(15):1093-102
1493193
J Biomed Mater Res. 1993 Aug;27(8):1019-28
8408114
Adv Protein Chem. 1985;37:161-245
3904348